טוען...
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
Background TAS-102 is a nucleoside antitumor agent consisting of trifluridine (FTD) and tipiracil hydrochloride (TPI). We investigated the recommended dose (RD) of TAS-102 plus irinotecan for metastatic colorectal cancer refractory to 5-fluorouracil (5-FU) and oxaliplatin. Methods This study was use...
שמור ב:
| הוצא לאור ב: | Invest New Drugs |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer US
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4768213/ https://ncbi.nlm.nih.gov/pubmed/26163340 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0271-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|